HOT TAKE: What’s Going On with LSD?

You’ve probably been getting a ton of news in your online feeds about MindMed’s recent approval from the FDA to test LSD as single-dose intervention for chronic anxiety. There’s a reason everyone is talking about it (even me!): the FDA’s nod towards LSD research for therapeutic purposes heralds a new era in mental health treatment. This progression reflects an evolving perspective on psychedelics, which, despite their controversial past (especially in the case of LSD), are now being revisited for their potential to rewrite the narratives of mental health care. As someone who once led an R&D portfolio exploring psychedelic medicine’s utility for a major corporate healthcare organization, I see these advances not just as a step forward but as a leap towards understanding and treating mental health complexities beyond the reductionist approaches that have long dominated the field. But it’s not all sunshine and roses (or in this case, psychedelic neon mushrooms and daisies); it’s important to consider the implications of this landmark LSD decision, both good and bad. <a href="https://medium.com/firing-and-wiring/the-promise-and-prudence-of-lsd-in-mental-health-treatment-20e4f0b73c4b">Read More</a>